PIM was identified as a STAT5 inhibitor by a high throughput screen based on STAT transcriptional activity and it decreased the survival of CML cells resistant tyrosine kinase inhibitors [96]. Here, STAT5B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.